Tags

Type your tag names separated by a space and hit enter

Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
Int J Clin Exp Pathol. 2014; 7(10):7297-303.IJ

Abstract

OBJECTIVE

To identify patients with endometrial cancer with potential Lynch-related DNA mismatch repair (MMR) protein expression defects and to explore the role of these defects in screening for LS.

METHODS

Endometrial cancers from 173 patients recruited to the Nanchong Central Hospital were tested for MMR (MLH1, MSH2, PMS2, and MSH6) protein expression using immunohistochemistry (IHC).

RESULTS

In the 173 tumor tissue samples, the expression loss rates of MSH6, MSH2, PMS2 and MLH1 protein were 16.18% (28/173), 12.14% (21/173), 7.51% (13/173) and 5.78% (10/173), respectively. The total loss rate of MMR protein was 29.89% (27/87). There were 19 patients with a family history of cancer, of which 18 patients demonstrated loss of expression of MMR protein. In the 22 abnormal MMR patients without family history, five families were found to have Lynch-associated cancer (colorectal cancer, endometrial cancer, ovarian cancer, stomach cancer) after follow-up for two years.

CONCLUSION

MMR proteins play an important role in the progress of endometrial cancer. The routine testing of MMR proteins in endometrial cancer can contribute to the screening of LS families, especially small families.

Authors+Show Affiliations

Department of Pathology Nanchong Central Hospital, North Sichuan Medical University Nanchong 637000, Sichuan, China.Department of Gynecology and Obstetrics Nanchong Central Hospital, North Sichuan Medical University Nanchong 637000, Sichuan, China.Department of Pathology Nanchong Central Hospital, North Sichuan Medical University Nanchong 637000, Sichuan, China.Department of Pathology Nanchong Central Hospital, North Sichuan Medical University Nanchong 637000, Sichuan, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25400828

Citation

Long, Qiongxian, et al. "Role of Endometrial Cancer Abnormal MMR Protein in Screening Lynch-syndrome Families." International Journal of Clinical and Experimental Pathology, vol. 7, no. 10, 2014, pp. 7297-303.
Long Q, Peng Y, Tang Z, et al. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families. Int J Clin Exp Pathol. 2014;7(10):7297-303.
Long, Q., Peng, Y., Tang, Z., & Wu, C. (2014). Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families. International Journal of Clinical and Experimental Pathology, 7(10), 7297-303.
Long Q, et al. Role of Endometrial Cancer Abnormal MMR Protein in Screening Lynch-syndrome Families. Int J Clin Exp Pathol. 2014;7(10):7297-303. PubMed PMID: 25400828.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families. AU - Long,Qiongxian, AU - Peng,Yong, AU - Tang,Zhirong, AU - Wu,Cailiang, Y1 - 2014/09/15/ PY - 2014/08/18/received PY - 2014/09/15/accepted PY - 2014/11/18/entrez PY - 2014/11/18/pubmed PY - 2015/7/7/medline KW - HNPCC KW - Lynch syndrome KW - endometrial cancer KW - immunohistochemistry KW - mismatch repair protein SP - 7297 EP - 303 JF - International journal of clinical and experimental pathology JO - Int J Clin Exp Pathol VL - 7 IS - 10 N2 - OBJECTIVE: To identify patients with endometrial cancer with potential Lynch-related DNA mismatch repair (MMR) protein expression defects and to explore the role of these defects in screening for LS. METHODS: Endometrial cancers from 173 patients recruited to the Nanchong Central Hospital were tested for MMR (MLH1, MSH2, PMS2, and MSH6) protein expression using immunohistochemistry (IHC). RESULTS: In the 173 tumor tissue samples, the expression loss rates of MSH6, MSH2, PMS2 and MLH1 protein were 16.18% (28/173), 12.14% (21/173), 7.51% (13/173) and 5.78% (10/173), respectively. The total loss rate of MMR protein was 29.89% (27/87). There were 19 patients with a family history of cancer, of which 18 patients demonstrated loss of expression of MMR protein. In the 22 abnormal MMR patients without family history, five families were found to have Lynch-associated cancer (colorectal cancer, endometrial cancer, ovarian cancer, stomach cancer) after follow-up for two years. CONCLUSION: MMR proteins play an important role in the progress of endometrial cancer. The routine testing of MMR proteins in endometrial cancer can contribute to the screening of LS families, especially small families. SN - 1936-2625 UR - https://www.unboundmedicine.com/medline/citation/25400828/Role_of_endometrial_cancer_abnormal_MMR_protein_in_screening_Lynch_syndrome_families_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25400828/ DB - PRIME DP - Unbound Medicine ER -